Skip to main content
OpenTrials
Completed

NCT Number: NCT00483132

Study of Treatment High Risk and/or Low Risk Acute Lymphoblastic leukémia(ALL) Adults Stage III

Improved outcome of high risk lymphoblastic leukemia (ALL) with laite high dose therapy.

High dose versus conventional therapy for adult low risk T-ALL and Lymphoblastic lymphoma (LBL).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Leukemia, Lymphocytic, Acute Hematologic Diseases Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Leukemia Leukemia, Lymphoid Lymphatic Diseases Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type Precursor Cell Lymphoblastic Leukemia-Lymphoma

Age range

15 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

INorbert IFRAH

Angers, Chu Angers, 49000, France

About this study

Comparison between two autograf therapeutic strategies in high risk patients Ramdomised comparison between maintenance treatment with or not interferon alpha 2 a

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ALL high risk or low risk or lymphoblastic lymphoma
  • age 15-55 years old
  • informed consent signed

Exclusion criteria

  • patients previously treated with a chemotherapy or alpha-interferon
  • ALL 3 (burkitt like)

Treatment and study plan

interferon alpha 2a

Drug

Primary outcomes

  1. overall survival

    Time frame: time to death

Secondary outcomes

  1. Efficacy of study treatments

    Time frame: time to end of treatment

Sponsors and collaborators

Lead sponsor

French Innovative Leukemia Organisation

Other

Registry information

Important dates

Study start
1994
Study completion
2002
First posted
Jun 6, 2007
Registry last updated
Jun 6, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.